452 related articles for article (PubMed ID: 18413796)
1. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
[TBL] [Abstract][Full Text] [Related]
2. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
3. Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761.
Connolly EC; Saunier EF; Quigley D; Luu MT; De Sapio A; Hann B; Yingling JM; Akhurst RJ
Cancer Res; 2011 Mar; 71(6):2339-49. PubMed ID: 21282335
[TBL] [Abstract][Full Text] [Related]
4. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
5. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.
Ganapathy V; Ge R; Grazioli A; Xie W; Banach-Petrosky W; Kang Y; Lonning S; McPherson J; Yingling JM; Biswas S; Mundy GR; Reiss M
Mol Cancer; 2010 May; 9():122. PubMed ID: 20504320
[TBL] [Abstract][Full Text] [Related]
7. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
Zhang M; Herion TW; Timke C; Han N; Hauser K; Weber KJ; Peschke P; Wirkner U; Lahn M; Huber PE
Neoplasia; 2011 Jun; 13(6):537-49. PubMed ID: 21677877
[TBL] [Abstract][Full Text] [Related]
8. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
9. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
Solorzano CC; Baker CH; Tsan R; Traxler P; Cohen P; Buchdunger E; Killion JJ; Fidler IJ
Clin Cancer Res; 2001 Aug; 7(8):2563-72. PubMed ID: 11489840
[TBL] [Abstract][Full Text] [Related]
10. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
[TBL] [Abstract][Full Text] [Related]
11. LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-β and BMP-associated proinflammatory and proangiogenic signals.
Flechsig P; Dadrich M; Bickelhaupt S; Jenne J; Hauser K; Timke C; Peschke P; Hahn EW; Gröne HJ; Yingling J; Lahn M; Wirkner U; Huber PE
Clin Cancer Res; 2012 Jul; 18(13):3616-27. PubMed ID: 22547771
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells.
Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K
Br J Cancer; 2010 Mar; 102(5):844-51. PubMed ID: 20145621
[TBL] [Abstract][Full Text] [Related]
14. Antimetastatic role of Smad4 signaling in colorectal cancer.
Zhang B; Halder SK; Kashikar ND; Cho YJ; Datta A; Gorden DL; Datta PK
Gastroenterology; 2010 Mar; 138(3):969-80.e1-3. PubMed ID: 19909744
[TBL] [Abstract][Full Text] [Related]
15. Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
Gore J; Imasuen-Williams IE; Conteh AM; Craven KE; Cheng M; Korc M
Cancer Lett; 2016 Aug; 379(1):143-53. PubMed ID: 27267807
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.
Bandyopadhyay A; Agyin JK; Wang L; Tang Y; Lei X; Story BM; Cornell JE; Pollock BH; Mundy GR; Sun LZ
Cancer Res; 2006 Jul; 66(13):6714-21. PubMed ID: 16818646
[TBL] [Abstract][Full Text] [Related]
17. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
18. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
[TBL] [Abstract][Full Text] [Related]
19. PKCalpha-induced drug resistance in pancreatic cancer cells is associated with transforming growth factor-beta1.
Chen Y; Yu G; Yu D; Zhu M
J Exp Clin Cancer Res; 2010 Aug; 29(1):104. PubMed ID: 20684793
[TBL] [Abstract][Full Text] [Related]
20. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
